Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Sells 5,114 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) EVP Joseph J. Larosa sold 5,114 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, April 7th. The shares were sold at an average price of $721.10, for a total value of $3,687,705.40. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of NASDAQ REGN traded down $16.47 during mid-day trading on Monday, reaching $722.37. 708,949 shares of the company’s stock were exchanged, compared to its average volume of 746,123. The firm has a market capitalization of $77.69 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 1.25 and a beta of 0.21. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.07 and a current ratio of 3.56. Regeneron Pharmaceuticals, Inc. has a 52-week low of $469.80 and a 52-week high of $747.42. The company’s 50-day moving average is $649.81 and its 200-day moving average is $627.41.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its quarterly earnings results on Friday, February 4th. The biopharmaceutical company reported $23.72 earnings per share for the quarter, topping analysts’ consensus estimates of $18.49 by $5.23. Regeneron Pharmaceuticals had a return on equity of 55.11% and a net margin of 50.24%. The business had revenue of $4.95 billion during the quarter, compared to analysts’ expectations of $4.49 billion. During the same period in the prior year, the business posted $8.72 EPS. The company’s revenue was up 104.4% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 45.56 earnings per share for the current fiscal year.

A number of research firms have weighed in on REGN. Bank of America lowered Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $675.00 to $575.00 in a research note on Wednesday, January 5th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $694.00 target price for the company in a research note on Monday, January 10th. SVB Leerink reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 14th. HC Wainwright reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 13th. Finally, StockNews.com started coverage on Regeneron Pharmaceuticals in a research note on Thursday, March 31st. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $724.22.

A number of institutional investors have recently made changes to their positions in the stock. Maryland State Retirement & Pension System boosted its holdings in Regeneron Pharmaceuticals by 3.5% during the 1st quarter. Maryland State Retirement & Pension System now owns 7,909 shares of the biopharmaceutical company’s stock valued at $5,524,000 after acquiring an additional 265 shares during the period. Atlas Private Wealth Advisors acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $693,000. Sound Income Strategies LLC raised its position in Regeneron Pharmaceuticals by 109.1% in the 1st quarter. Sound Income Strategies LLC now owns 69 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 36 shares in the last quarter. RK Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $284,000. Finally, Massmutual Trust Co. FSB ADV raised its position in Regeneron Pharmaceuticals by 9.4% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 3,341 shares of the biopharmaceutical company’s stock valued at $2,333,000 after purchasing an additional 287 shares in the last quarter. Institutional investors own 82.97% of the company’s stock.

About Regeneron Pharmaceuticals (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Stories

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.